Medical Value of SARS-CoV-2 Spike Protein

Get high medical value with Access SARS-CoV-2 IgG assay as it detects antibodies against the virus spike protein that may be more likely to confer immunity.
Medical Value of SARS-CoV-2 Spike Protein

There is an increased demand for serology testing for SARS-CoV-2 to identify people who have been exposed to the virus and who may have developed an immune response. However, there are questions about which viral protein to use as an antigen for serology testing. Based on the information we have, the the receptor-binding domain to viral spike protein is perceived as the obvious candidate.1

The Coronavirus

Illustration of coronavirus with four structural proteins

A coronavirus contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.  

The coronavirus gets its name from the spike like protrusions that look like a crown. These viruses use the spike protein to bind to proteins on the host cell to gain entry. In the case of SARS-CoV-2, the spike proteins bind angiotensin-converting enzyme 2 (ACE2 receptor) on human cells with high affinity.2

The Value of the Spike Protein

Though the coronavirus uses many different proteins to replicate and invade cells, the spike protein is the major surface protein that it uses to bind to a receptor. After the spike protein binds to the human cell receptor, the viral membrane fuses with the human cell membrane, allowing the genome of the virus to enter human cells and begin infection.3

Studies have also shown that the S protein plays the most important roles in viral attachment, fusion and entry, and it serves as a target for development of antibodies, entry inhibitors and vaccines.4–10

The coronavirus spike protein mediates entry into host cells by attaching to a receptor on respiratory cells called angiotensin-converting enzyme 2, or ACE2,11 .

The [SARS-CoV-2] S protein plays the most important roles in viral attachment, fusion and entry, and it serves as a target for development of antibodies, entry inhibitors and vaccines.14
Tai, W., He, L., Zhang, X. et al.
Cell Mol Immunol (2020)

Learn more about the Access SARS-CoV-2 IgG assay.

1Petherick, A. Developing antibody tests for SARS-CoV-2. April 04, 2020. Lancet. DOI:
2Howes L. Structure of novel coronavirus spike protein solved in just weeks. Chemical & Engineering News. February 19, 2020. Vol. 98, Issue 8. [Accessed: May 1, 2020]
3Saplakoglu Y. Coronavirus ‘spike’ protein just mapped, leading way to vaccine. February 19, 2020. [Accessed May 1, 2020]
4Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B. J. & Jiang, S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009).
5Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F. & Jiang, S. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21, 131–143 (2017).
6Lu, L. et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014).
7Du, L. et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7, 13473 (2016).
8He, Y., Li, J., Heck, S., Lustigman, S. & Jiang, S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 80, 5757–5767 (2006).
9Liu, S. et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363, 938–947 (2004).
10Wang, Q., Wong, G., Lu, G., Yan, J. & Gao, G. F. MERS-CoV spike protein: targets for vaccines and therapeutics. Antivir. Res. 133, 165–177 (2016).
11Pappas S. Scientists figure out how new coronavirus breaks into human cells. Live Science. March 11, 2020. [Accessed: May 1, 2020]
12Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., Lu, Q., Li, X., Sun, Q., Liu, J., Fan, C., Huang, W., Xu, M., & Wang, Y. (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerging microbes & infections, 9(1), 680–686.
13Chen, X., Li, R., Pan, Z. et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol (2020).
14Tai, W., He, L., Zhang, X. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol (2020).

All Beckman Coulter products may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.

Kathleen Orland
Kathleen Orland
Kathleen Orland currently serves as senior vice president and general manager for Beckman Coulter’s Clinical Chemistry Immunoassay (CCIA) business unit, leading product strategy and new product development programs across eight global sites.

Related Articles

Automation for All

Automation for All

With solutions available for every sized lab, automation is now a necessity to optimize patient care.
Fully-Automated Urinalysis Launches at AACC

Fully-Automated Urinalysis Launches at AACC

Launch of the fully automated DxU Iris Workcell at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
Avoiding Disruptions in Laboratory Workflow During Challenging Times

Avoiding Disruptions in Laboratory Workflow During Challenging Times

Today’s laboratories face many disruptions in workflow that delay patient care. Learn how automated urinalysis solutions can free-up time consuming bottlenecks.